Mejia M C, Navarro S, Pellin A, Castel V, Llombart-Bosch A
Department of Pathology, Medical School, University of Valencia, Spain.
Anticancer Res. 1998 Mar-Apr;18(2A):801-6.
Prognosis in neuroblastoma is based upon several clinical factors such as age, tumoral staging and other genetic factors like N-myc oncogene amplification or deletion of the short arm of chromosome 1 (del 1p). Recent reports indicate that bcl-2 protein expression is associated with a poor outcome in patients with neuroblastoma.
We present a study of 80 cases from the files of the Spanish neuroblastoma study group (N-II-92) analysing bcl-2 protein expression by means of immunohistochemical methods and its relation with other parameters such as histopathology, PCNA expression, N-myc amplification and DNA study of apoptosis.
We found a statistical correlation between bcl-2 protein expression and unfavourable histopathology, N-myc amplification and PCNA nuclear staining. An inverse relation between bcl-2 staining and apoptosis was detected.
Based on present findings it can be concluded that the determination of bcl-2 protein provides prognostic information when associated with other biological factors involved in neuroblastomas.
神经母细胞瘤的预后基于多种临床因素，如年龄、肿瘤分期以及其他遗传因素，如N - myc癌基因扩增或1号染色体短臂缺失（1p缺失）。近期报告表明，bcl - 2蛋白表达与神经母细胞瘤患者的不良预后相关。
我们对西班牙神经母细胞瘤研究组（N - II - 92）档案中的80例病例进行了研究，通过免疫组织化学方法分析bcl - 2蛋白表达及其与其他参数的关系，这些参数包括组织病理学、增殖细胞核抗原（PCNA）表达、N - myc扩增以及细胞凋亡的DNA研究。
我们发现bcl - 2蛋白表达与不良组织病理学、N - myc扩增和PCNA核染色之间存在统计学相关性。检测到bcl - 2染色与细胞凋亡呈负相关。
基于目前的研究结果可以得出结论，当与神经母细胞瘤涉及的其他生物学因素相关联时，bcl - 2蛋白的检测可提供预后信息。
